Zai Lab Limited announced that the 2023 National Reimbursement Drug List (NRDL) released by China?s National Healthcare Security Administration (NHSA) has been updated to include the following medicines and indications: VYVGART® (efgartigimod alfa injection) is included for the first time in the NRDL for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive; NUZYRA® (omadacycline) is included for its oral formulation for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI); and ZEJULA® (niraparib) is renewed for the maintenance treatment of adult patients with platinum-sensitive, first-line and recurrent ovarian cancer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.69 USD | -1.55% |
|
+3.63% | -27.95% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.95% | 1.98B | |
+0.46% | 91.38B | |
-3.16% | 38.68B | |
-9.63% | 33.58B | |
+72.31% | 27.84B | |
-12.63% | 16.05B | |
-0.16% | 13.48B | |
-9.38% | 11.73B | |
+172.59% | 10.74B | |
-49.44% | 10.39B |
- Stock Market
- Equities
- ZLAB Stock
- News Zai Lab Limited
- Zai Lab Limited Announces the First Listing of VYVGART(R) (efgartigimod alfa injection) and Other Updates in China's National Reimbursement Drug List